Current cancer drug targets最新文献_第5页

Spinal KCC2 Mediates the Modulation Effect of HDAC2 on Bone Cancer Pain in Rats. 脊髓KCC2介导HDAC2对大鼠骨癌疼痛的调节作用。

IF 2.3 4区医学

Current cancer drug targets Pub Date : 2025-02-24 DOI: 10.2174/0115680096356509250117092430

Tongxuan Wang, Yalin Li, Xinran Hou, Qulian Guo, Yingqi Weng

{"title":"Spinal KCC2 Mediates the Modulation Effect of HDAC2 on Bone Cancer Pain in Rats.","authors":"Tongxuan Wang, Yalin Li, Xinran Hou, Qulian Guo, Yingqi Weng","doi":"10.2174/0115680096356509250117092430","DOIUrl":"https://doi.org/10.2174/0115680096356509250117092430","url":null,"abstract":"Background: Bone cancer pain is a global medical concern with limited treatment options that significantly reduce the quality of life for cancer patients. Therefore, identifying a promising therapeutic target for bone cancer pain is urgently needed.Objective: Our previous research indicated that KCC2 may be associated with the modulation of HDAC2 in a rat model of bone cancer pain. The current study aimed to investigate whether KCC2 in the lumbar spinal cord is a key downstream molecule in the modulation of HDAC2 related to bone cancer pain.Methods: In this study, we assessed the expression levels of KCC2 and HDAC2 in the lumbar spinal cord of rats with bone cancer pain using Western blotting and RT-PCR. Mechanical hyperalgesia was evaluated using Von Frey hairs, and immunofluorescence was employed to localize KCC2 in central nervous system cells.Results: The expression of KCC2 was down-regulated in a time-dependent manner in the lumbar spinal cord of rats with bone cancer pain. Furthermore, the use of an RNA-interfering lentivirus targeting HDAC2 restored KCC2 expression and alleviated mechanical hyperalgesia in these rats. Notably, the analgesic effect of the HDAC2-targeting lentivirus was completely reversed by the KCC2 inhibitor VU0240551.Conclusion: KCC2 in the lumbar spinal cord mediated the modulation of HDAC2 in rat models of bone cancer pain, suggesting that KCC2 could be a promising therapeutic target for treating bone cancer pain.","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advanced Engineered Nanoplatforms to Overcome Biological Barriers for Targeting Brain Tumors. 先进的工程纳米平台克服靶向脑肿瘤的生物屏障。

IF 2.3 4区医学

Current cancer drug targets Pub Date : 2025-02-20 DOI: 10.2174/0115680096355101250120114819

Shaheen Sultana, Jyoti Gupta, Vikram Sharma, Komal Gupta, Gayatri Khosla, Darshna Mishra

{"title":"Advanced Engineered Nanoplatforms to Overcome Biological Barriers for Targeting Brain Tumors.","authors":"Shaheen Sultana, Jyoti Gupta, Vikram Sharma, Komal Gupta, Gayatri Khosla, Darshna Mishra","doi":"10.2174/0115680096355101250120114819","DOIUrl":"https://doi.org/10.2174/0115680096355101250120114819","url":null,"abstract":"Effective drug delivery to the brain is critically hindered by the blood-brain barrier (BBB), a selective barrier that complicates treatment for central nervous system (CNS) disorders, including brain tumors. Recent innovations in pharmaceutical sciences have introduced new strategies to surmount this challenge and enhance therapeutic efficacy. This review aims to assess recent advancements in engineered nanoplatforms designed to overcome the BBB, with a focus on their application in brain tumor targeting. It seeks to evaluate different drug delivery strategies and formulations that enhance brain penetration, improve targeting precision, and minimize systemic side effects. A comprehensive review of the literature and recent studies on brain-targeting strategies was conducted. The review examined the strategies to prolong blood circulation time and analyzed particularly the PEGylation approach, lipid-based nanocarrier, albumin binding strategies and red blood cell-based delivery. It also explored various strategies (e.g., peptides, prodrug, antibodies, nanotechnology, ligand-based delivery) and subcellular targeting techniques aimed at enhancing brain drug delivery and cellular uptake. PEGylation was found to significantly improve the ability of nano carriers to penetrate brain tumors by reducing macrophage-mediated clearance. Nanotechnology-based strategies coupled with ligand-based approaches effectively enhance brain delivery. Subcellular targeting strategies facilitated endolysosomal escape, leading to better therapeutic agent retention within brain tumor cells. Advances in nanotechnology and targeting strategies offer promising solutions for overcoming the BBB and improving brain tumor treatment. These novel strategies significantly enhance brain targeting while minimizing systemic effects. Continued research is essential to optimize these methods and achieve more effective therapeutic outcomes.","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Nrf2 in Glioma: Therapeutic Targeting Strategies. Nrf2在胶质瘤中的作用：治疗靶向策略。

IF 2.3 4区医学

Current cancer drug targets Pub Date : 2025-02-14 DOI: 10.2174/0115680096331620250119111525

Mohammad Sadra Harifi-Mood, Effat Alemzadeh, Danyal Barati, Amir Hossein Dehghani, Fatemeh Zahra Siroosi, Michael Aschner, Fariborz Samini, Saeed Samarghandian, Tahereh Farkhondeh

{"title":"The Role of Nrf2 in Glioma: Therapeutic Targeting Strategies.","authors":"Mohammad Sadra Harifi-Mood, Effat Alemzadeh, Danyal Barati, Amir Hossein Dehghani, Fatemeh Zahra Siroosi, Michael Aschner, Fariborz Samini, Saeed Samarghandian, Tahereh Farkhondeh","doi":"10.2174/0115680096331620250119111525","DOIUrl":"https://doi.org/10.2174/0115680096331620250119111525","url":null,"abstract":"Cancer is one of the most challenging diseases to cure due to its complexity. Gli-oma, as a neuroepithelial cancer of the glial cells, is one of the rarest malignancies which has a low survival rate. The exact risk factors of glioma are still not clear, but allergy, ionizing radiation, and hereditary factors are reported to be associated with glioma. Nrf2 as an antiox-idant regulator has been reported to be highly expressed in malignances tissues like glioma. Nrf2 regulates the expression of various antioxidant and cytoprotective genes. In gliomas, Nrf2 activation helps tumor cells combat oxidative stress by enhancing the production of de-toxifying enzymes (e.g., glutathione peroxidase, NADPH quinone oxidoreductase). This al-lows glioma cells to survive and proliferate in toxic tumor microenvironments rich in reactive oxygen species (ROS). Although the role of Nrf2 in the apoptosis of cancerous glial cells is not clear yet, it has been shown that Nrf2 inhibition via different methods can increase the efficiency of the chemo-therapy agents to treat glioma. Elevated Nrf2 activity has been linked to drug resistance in gliomas. The activation of Nrf2 increases the expression of multidrug resistance-associated proteins (MRPs) and other detoxifying enzymes, which limit the effectiveness of chemother-apeutic agents like temozolomide (TMZ). Nrf2 inhibitors can suppress the signaling pathway of Nrf2 and decrease the expression of detoxifying enzymes like SOD, CAT, GPX, and GCL, which can increase the efficiency of chemotherapy agents. Using drugs that inhibit the Nrf2 expression in combination with classical chemotherapy agents can be a promising procedure to decrease chemoresistance and be effective in increasing the survival rate of patients with glioma. In this study, we focused on the association of glioma and Nrf2 expression and its targeting as a new therapeutic approach in glioma treatment.","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Groundbreaking mRNA Lung Cancer Vaccine Trials: A New Dawn in Cancer Treatment. 突破性的mRNA肺癌疫苗试验：癌症治疗的新曙光

IF 2.3 4区医学

Current cancer drug targets Pub Date : 2025-02-14 DOI: 10.2174/0115680096360059250131075456

Md Sadique Hussain, Ayesha Sultana, Ajay Singh Bisht, Gaurav Gupta

{"title":"Groundbreaking mRNA Lung Cancer Vaccine Trials: A New Dawn in Cancer Treatment.","authors":"Md Sadique Hussain, Ayesha Sultana, Ajay Singh Bisht, Gaurav Gupta","doi":"10.2174/0115680096360059250131075456","DOIUrl":"https://doi.org/10.2174/0115680096360059250131075456","url":null,"abstract":"The advent of mRNA vaccines has heralded a transformative era in oncology, exemplified by the BNT116 mRNA lung cancer vaccine. Leveraging the same ground-breaking technology as COVID-19 vaccines, BNT116 delivers tumor-specific genetic in-structions to the immune system, targeting non-small cell lung cancer (NSCLC), the most prevalent lung cancer subtype. This approach contrasts with conventional therapies that lack precision and often damage healthy tissues. By encoding tumor antigens, BNT116 educates cytotoxic T cells to recognize and eradicate malignant cells, aligning with the principles of precision medicine. Early-phase clinical trials (e.g., NCT05142189) have demonstrated a favorable safety profile and promising antitumor activity, with ongoing re-search exploring its use in combination therapies, such as checkpoint inhibitors. Despite logistical challenges, such as mRNA instability and cold chain requirements, advances in lipid nanoparticle delivery systems are enhancing vaccine stability and efficacy. The adaptability of mRNA technology positions it as a cornerstone for personalized oncology, with potential applications extending to other cancers. Success in the BNT116 trials could redefine NSCLC treatment paradigms, offering a targeted, less cytotoxic alternative. This innovation can not only improve therapeutic outcomes, but also pave the way for preven-tive cancer vaccines, signaling a new dawn in cancer treatment.","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic Potential of Terpenes in Lung Cancer: Modulation of 4-Oxo-Retinoic Acid, TNF-α, NF-κB, and HDAC2 Pathways. 萜烯在肺癌中的治疗潜力：调节4-氧维甲酸、TNF-α、NF-κB和HDAC2通路。

IF 2.3 4区医学

Current cancer drug targets Pub Date : 2025-02-14 DOI: 10.2174/0115680096353438250130070422

Janmejay Pant, Payal Mittal, Lovedeep Singh

{"title":"Therapeutic Potential of Terpenes in Lung Cancer: Modulation of 4-Oxo-Retinoic Acid, TNF-α, NF-κB, and HDAC2 Pathways.","authors":"Janmejay Pant, Payal Mittal, Lovedeep Singh","doi":"10.2174/0115680096353438250130070422","DOIUrl":"https://doi.org/10.2174/0115680096353438250130070422","url":null,"abstract":"Non-small cell lung cancer (NSCLC) includes various epithelial malignancies, such as squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Despite ad-vancements in surgical resection, chemoradiotherapy, and multimodal therapies, NSCLC prognosis remains challenging due to its complex molecular landscape, drug resistance, and high treatment costs. Recent research highlights the potential of natural compounds, particularly terpenes and terpenoids, derived from essential oils (EOs), to enhance NSCLC treatment. These compounds exhibit anticancer properties and modulate key pathways like the 4-oxo-retinoic acid pathway, TNF-α signaling, NF-κB activation, and histone deacety-lases (HDACs). Retinoids, a subclass of terpenes, show both chemopreventive and thera-peutic benefits, especially when combined with other agents, though challenges in dosing and delivery methods limit their clinical application. Terpenes may also synergize with emerging therapies, such as antiangiogenic treatments and immunotherapy, to improve outcomes. Biomarkers, including genomic, epigenomic, and proteomic markers, play a critical role in predicting responses to terpene-based treatments, supporting personalized medicine. The integration of terpenes into existing regimens, in combination with conven-tional therapies, holds promise in overcoming clinical challenges, improving patient out-comes, and advancing natural compound use in modern oncology. Future research should focus on optimizing terpene therapies and addressing clinical hurdles.","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

7-Dehydrocholesterol Reductase Activates the Hedgehog Pathway by Regulating Cholesterol to Promote the Development of Triple-Negative Breast Cancer. 7-脱氢胆固醇还原酶通过调节胆固醇激活Hedgehog通路促进三阴性乳腺癌的发展

IF 2.3 4区医学

Current cancer drug targets Pub Date : 2025-02-14 DOI: 10.2174/0115680096363566250119155918

Shuang Qiu, Yu Sun, Yuanyuan Liu, Jinyu Yang, Xin Chen, Di Wu, Li Li, Jianwei Sun

{"title":"7-Dehydrocholesterol Reductase Activates the Hedgehog Pathway by Regulating Cholesterol to Promote the Development of Triple-Negative Breast Cancer.","authors":"Shuang Qiu, Yu Sun, Yuanyuan Liu, Jinyu Yang, Xin Chen, Di Wu, Li Li, Jianwei Sun","doi":"10.2174/0115680096363566250119155918","DOIUrl":"10.2174/0115680096363566250119155918","url":null,"abstract":"Background: Cholesterol has been shown to be a potential risk factor for the occurrence and progression of breast cancer. This study aimed to investigate the regulation of DHCR7 in cholesterol synthesis and its role in Hedgehog (Hh) signaling pathway activation, as well as its impact on the progression of triple-negative breast cancer (TNBC).Methods: We analyzed the gene expression data from the GSE76275 data set by bioinformatics analysis to determine the expression of cholesterol-related genes in triple-negative breast cancer. In the triple-negative breast cancer cell lines, including BT-549 and MDA-MB-231, RNA interference gene knockout was used to evaluate the functional impact of DHCR7. In addition, the SMO mutant (SMOV329F) with anti-cholesterol binding inhibition was introduced to determine its interaction with the pathway changes mediated by DHCR7. Cell proliferation, migration, and signaling pathway activation were assessed through Western blotting, CCK-8 assay, transwell migration assay, and qPCR.Results: DHCR7 expression was significantly elevated in TNBC tissues and cell lines, enhancing the Hh pathway activity through cholesterol modulation. Knocking down DHCR7 and the SMOV329F mutation both reduced the expression of Hedgehog-related proteins and inhibited cell proliferation and migration abilities. However, the SMOV329F mutation re-versed the inhibitory effect of knocking down DHCR7 on TNBC cells.Conclusion: DHCR7 activates the Hedgehog pathway by regulating cholesterol to promote the development of TNBC. These findings provide insights into the regulatory roles of DHCR7 in cholesterol-related pathways and Hh signaling in TNBC cells, offering potential therapeutic targets for TNBC treatment.","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Utilization of DNA Replication factor MCM2 by Cancer. DNA复制因子MCM2在肿瘤中的应用。

IF 2.3 4区医学

Current cancer drug targets Pub Date : 2025-02-13 DOI: 10.2174/0115680096349638250117101910

Yuwei Yuan, Tian Zeng, Anbo Gao, Yang Guan, Qun-Feng Zhang, Yukun Li, Hui Tan, Juan Zou

引用次数: 0

Recent Advances in Cutaneous Carcinoma Therapy Through Integrated Use of Immunotherapy and Nanotechnology. 结合免疫疗法和纳米技术治疗皮肤癌的最新进展。

IF 2.3 4区医学

Current cancer drug targets Pub Date : 2025-02-12 DOI: 10.2174/0115680096349248250113093025

Tenzin Tsering Dongsar, Kartik Bajaj, Tenzin Sonam Dongsar, Ahbab Ali, Nazeer Hasan, Farhan Jalees Ahmad

{"title":"Recent Advances in Cutaneous Carcinoma Therapy Through Integrated Use of Immunotherapy and Nanotechnology.","authors":"Tenzin Tsering Dongsar, Kartik Bajaj, Tenzin Sonam Dongsar, Ahbab Ali, Nazeer Hasan, Farhan Jalees Ahmad","doi":"10.2174/0115680096349248250113093025","DOIUrl":"https://doi.org/10.2174/0115680096349248250113093025","url":null,"abstract":"Skin cancer is one of the most lethal cancers today, posing significant challenges to public health and potentially impacting global health and economic stability. Due to its high rate of incidence, innovative and effective treatments are crucial. Among these, immunothera-peutic approaches have emerged as transformative, offering new hope by harnessing the body's immune system to target and eliminate cancerous cells. Immunotherapy has changed the treatment landscape for skin cancer, providing options such as checkpoint inhibitors and adoptive cell transfer therapies that specifically enhance immune activity against tumors. De-spite these advancements, the broader adoption of immunotherapeutic modalities is challeng-ing due to concerns about their toxicity and variable efficacy. The side effects, such as im-mune-related adverse events, can be severe and sometimes limit their use. In response to these challenges, nanotechnology in cancer treatment has gained significant attention. Nanotechnol-ogy-based approaches show promise in improving the delivery and effectiveness of cancer therapies, particularly for skin cancer immunotherapy. Nanoparticles can deliver therapeutic agents directly to tumors, minimizing systemic toxicity and enhancing treatment precision. These strategies also boost the immune system's ability to target cancer cells while overcom-ing the limitations of current immunotherapies. This review explores various anticancer thera-peutic approaches for managing skin cancer, focusing on immunotherapy and its challenges. It highlights how integrating nanotechnology with cancer immunotherapy offers a promising av-enue for enhancing treatment efficacy and safety. The review also provides an overview of re-cent advancements in skin cancer treatment, showcasing how these innovative strategies are paving the way for more effective and less toxic therapeutic options in combating one of the deadliest cancers.","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Comprehensive Review on Anticancer Potential of Pulicaria Plants and their Derivatives. 茯苓属植物及其衍生物抗癌潜力综述。

IF 2.3 4区医学

Current cancer drug targets Pub Date : 2025-02-12 DOI: 10.2174/0115680096358261250115114608

Tahere Barabadi, Hossein Rahimi, Seyed Mahdi Mohamadi-Zarch, Seyyed Majid Bagheri

{"title":"A Comprehensive Review on Anticancer Potential of Pulicaria Plants and their Derivatives.","authors":"Tahere Barabadi, Hossein Rahimi, Seyed Mahdi Mohamadi-Zarch, Seyyed Majid Bagheri","doi":"10.2174/0115680096358261250115114608","DOIUrl":"https://doi.org/10.2174/0115680096358261250115114608","url":null,"abstract":"The genus Pulicaria, belonging to the Asteraceae family, includes 100 species distributed from Europe to North Africa and Asia, especially around the Mediterranean. A number of extracts and compounds of this genus have been found to have anticancer effects on various cancer cell lines. Google, PubMed, Web of Science and Scopus databases were searched for articles related to Pulicaria or its isolated compounds. The search was conduct-ed using various keywords, including \"Pulicaria and anticancer activity\". After the review, the relevant articles were summarized and included in the review article. Fortunately, the re-sults of this review showed that relatively comprehensive studies have been conducted in this field, and the presence of various compounds in these plants can be used in cancer re-search. The results of our review showed that Pulicaria vulgaris has the strongest effect and Pulicaria dysenterica has the weakest effect on cancer cells. Future studies should focus on finding purer compounds and investigating the anticancer effects of these compounds. These herbal compounds can also be used alongside standard drugs to treat cancer, especially to reduce the effect of drug resistance.","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Review of the Progress in the Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma. 肺肉瘤样癌的诊断与治疗进展综述。

IF 2.3 4区医学

Current cancer drug targets Pub Date : 2025-02-07 DOI: 10.2174/0115680096341070250109074108

Dongying Liao, Jiayu Liu, Qingpeng Jin, Xiaoqun Wang, Na Wang, Yingjie Jia, Fanming Kong

引用次数: 0